Background: Lipopolysaccharide (LPS) of Helicobacter pylori (Hp) bacteria causes disintegration of gastric tissue cells in vitro. It has been suggested that interleukin (IL)-33 is involved in healing gastric injury. Aim: To elucidate whether Hp LPS affects regeneration of gastric barrier initiated by IL-33. Methods: Primary gastric epithelial cells or fibroblasts from Caviae porcellus were transfected with siRNA IL-33. Such cells, not exposed or treated with LPS Hp, were sub-cultured in the medium with or without exogenous IL-33. Then cell migration was assessed in conjunction with oxidative stress and apoptosis, activation of extracellular signal-regulated kinase (Erk), production of collagen I and soluble ST2 (IL-33 decoy). Results: Control cells not treated with LPS Hp migrated in the presence of IL-33. The pro-regenerative activity of IL-33 was related to stimulation of cells to collagen I production. Wound healing by cells exposed to LPS Hp was inhibited even in the presence of IL-33. This could be due to increased oxidative stress and apoptosis in conjunction with Erk activation, sST2 elevation and modulation of collagen I production. Conclusions: The recovery of gastric barrier cells during Hp infection potentially can be affected due to downregulation of pro-regenerative activity of IL-33 by LPS Hp.
The metabolic syndrome, often accompanied by hepatic manifestations, is a high-risk factor for developing cardiovascular disease. Patients with metabolic dysfunction associated with steatohepatic disease (MASDL) are at significant risk of developing coronary artery disease. Atherosclerosis is a systemic inflammatory disorder in which several factors, including dietary or infectious factors, can cause an inflammatory response. Helicobacter pylori (HP) bacteria have been implicated in the progression of proatherogenic vascular endothelial lesions, moreover, our previous study in an experimental in vivo model of Cavia porcellus showed that HP components and high-fat substances acted synergistically in promoting vascular endothelial inflammation, leading to an early onset of a proatherogenic environment. In the present study, our goal was to determine the contribution of HP components to the development of hepatic manifestations of metabolic syndrome in an experimental model. Our results showed that HP infection in animals exposed to a high-fat diet increased oxidative stress and lipid peroxidation, followed by endothelial lipid deposition, impaired endothelial apoptosis, cell lysis, and increased vascular stiffness. Finally, histopathological analysis of liver tissue showed signs of MASLD development in HP-infected animals fed a high-fat diet.
To promote facile and efficient synthesis of segmented covalent networks, we developed a cross-linking process with reactive polymeric components in a system without catalysts or side products. To achieve the direct formation of amphiphilic networks, an addition reaction was performed between the polyesters containing carboxyl terminal groups with pendant groups distributed along poly(2-isopropenyl-2-oxazoline) chains. Covalent cross-linking was achieved from predetermined amounts of components dissolved in DMSO at 140 °C. To tune the properties of the resulting networks, the composition and length of the polyester segments and the degree of cross-linking were changed in the feed. The chemical structure of the networks was characterized using Fourier transform infrared-attenuated total reflection spectroscopy and 13C magic-angle spinning NMR. The swelling ability of the formed networks was investigated in aqueous and organic media. Moreover, mechanical properties were tested during uniaxial compression. The cytocompatibility of the scaffolds was confirmed by MTT assay. Through the results obtained, the first report describing the cross-linking of polyesters on hydrophilic PiPOx was provided to prepare new, biocompatible materials with tuneable properties that are promising for potential biomedical applications.
Bioactive calcium phosphate ceramics (CaPs) are one of the building components of the inorganic part of bones. Synthetic CaPs are frequently used as materials for filling bone defects in the form of pastes or composites; however, their porous structure allows modification with active substances and, thus, subsequent use as a drug carrier for the controlled release of active substances. In this study, four different ceramic powders were compared: commercial hydroxyapatite (HA), TCP, brushite, as well as HA obtained by wet precipitation methods. The ceramic powders were subjected to physicochemical analysis, including FTIR, XRD, and determination of Ca/P molar ratio or porosity. These techniques confirmed that the materials were phase-pure, and the molar ratios of calcium and phosphorus elements were in accordance with the literature. This confirmed the validity of the selected synthesis methods. CaPs were then modified with the antibiotic clindamycin. Drug release was determined on HPLC, and antimicrobial properties were tested against Staphylococcus aureus. The specific surface area of the ceramic has been demonstrated to be a factor in drug release efficiency.
In this study, porous networks were efficiently prepared by crosslinking hydrophilic poly(2-isopropenyl-2-oxazoline) (PiPOx) with dicarboxylic polyesters (HOOC–PLA–COOH or HOOC–PCL–COOH) in the presence of sodium chloride as a water-soluble porogen. Importantly, by using a relatively simple synthetic protocol, the resulting spongy materials were freely formed to the desired size and shape while maintaining stable dimensions. According to the SEM data, the porous 3D structure can be altered by the pore dimensions, which are dependent on the porogen crystal size. After porosity characterization, the mechanical properties were also evaluated via uniaxial compression and tensile tests. The porous networks formed hydrogels with a high water absorption capacity. Finally, after showing cytocompatibility by the MTT assay, we also demonstrated the applicability of the porous hydrogels as scaffolds for cell cultivation. The presented results suggest that this type of hydrogels is a promising material for tissue engineering.
This study highlights the potential of nanoparticle-encapsulated colchicine as a safer and more effective alternative to free colchicine for treating atherosclerotic vascular disease (ASCVD). While colchicine is known for its anti-inflammatory properties, its dose-dependent toxicity limits long-term clinical use. To address this issue, colchicine was encapsulated in polymeric nanoparticles synthesized through a microfluidic method using methylated β-cyclodextrin as the initiator. The resulting formulation achieved an encapsulation efficiency of 30% and a drug loading capacity of 75%, indicating a high payload capability. This approach not only demonstrated high drug-loading efficiency but also enabled controlled release, with approximately 60% of the drug being released over 96 h. The nanoparticle formulation preserved colchicine’s ability to inhibit foam cell formation—a critical event in the progression of atherosclerosis—while significantly reducing toxicity to eukaryotic cells. Transmission electron microscopy revealed that cells treated with nanoparticle-bound colchicine maintained normal morphology, unlike those exposed to free colchicine, which rapidly accumulates intracellularly and disrupts cell function. In vivo evaluation confirmed the safety of the formulation, showing no adverse effects on the liver, kidneys, or heart, as indicated by stable levels of ALT, AST, creatinine, and cardiac troponin I. Biodistribution studies with fluorescently labeled nanoparticles further suggested accumulation in tissues such as the heart and liver, highlighting the potential therapeutic relevance of colchicine-loaded nanoparticles for cardiovascular applications. Given these findings, the nanoparticle-based colchicine formulation presents a favorable efficacy and safety profile, warranting further preclinical development and eventual clinical evaluation.